How has Celldex Therapeutics's other commercial liabilities changed year-over-year?

Celldex Therapeutics's other commercial liabilities increased by 50.9% year-over-year, from $25.46M to $38.42M.

What is the long-term trend for Celldex Therapeutics's other commercial liabilities?

Over 5 years (2020 to 2025), Celldex Therapeutics's other commercial liabilities has grown at a 40.9% compound annual growth rate (CAGR), from $8.46M to $47.03M.

Celldex Therapeutics CLDX Other Commercial Liabilities

Other Commercial Liabilities at other companies

AmgenAMGN

——

IncyteINCY

——

Arcutis Biotherapeutics, Inc.ARQT

——

Capricor TherapeuticsCAPR

——

Viridian Therapeutics, Inc.VRDN

——

Dianthus TherapeuticsDNTH

——

Other financials

Income statement

See full

Revenue$15.0K-97.8%

Operating income-$84.4M-34.6%

Net income-$78.7M-46.3%

EPS (diluted)-$1.18-45.7%

Balance sheet

See full

Cash & equivalents$35.7M+109%

Total debt$1.9M-44.3%

Total equity$456.2M-35.1%

Total assets$511.3M-30.9%

Cash flow

See full

Operating cash flow-$65.6M-20.6%

CapEx$1.6M+518%

Free cash flow-$67.2M-23.0%

Valuation

See full

Market cap$2.59B+75.2%

Enterprise value$2.55B+74.4%

P/S2,989.2×+2,794×

Profitability

See full

Operating margin-35,688.5%-39,114pp

Net margin-32,753.6%-35,519pp

FCF margin-26,125.8%-28,907pp

Returns & leverage

See full

Return on equity-48.9%-498pp

Debt / equity0×0.0×

Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Celldex Therapeutics's other commercial liabilities?: Celldex Therapeutics (CLDX) reported other commercial liabilities of $38.42M in Q1 2026.
How has Celldex Therapeutics's other commercial liabilities changed year-over-year?: Celldex Therapeutics's other commercial liabilities increased by 50.9% year-over-year, from $25.46M to $38.42M.
What is the long-term trend for Celldex Therapeutics's other commercial liabilities?: Over 5 years (2020 to 2025), Celldex Therapeutics's other commercial liabilities has grown at a 40.9% compound annual growth rate (CAGR), from $8.46M to $47.03M.